Phathom Pharmaceuticals (PHAT) Shares Outstanding (Weighted Average) (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Shares Outstanding (Weighted Average) data on file, last reported at $82.1 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $82.1 million, up 14.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $82.1 million (up 14.01% YoY), and the FY2025 annual result was $72.9 million, up 15.42% from the prior year.
• Shares Outstanding (Weighted Average) grew to $82.1 million in Q1 2026 per PHAT's latest filing, from $72.9 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $82.1 million in Q1 2026 and troughed at $38.0 million in Q1 2022.
• A 5-year average of $56.6 million and a median of $58.4 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Weighted Average) climbed 2.9% in 2022, then surged 37.82% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $39.1 million in 2022, then soared by 31.11% to $51.3 million in 2023, then gained by 23.18% to $63.2 million in 2024, then gained by 15.42% to $72.9 million in 2025, then increased by 12.52% to $82.1 million in 2026.
• Business Quant data shows PHAT's Shares Outstanding (Weighted Average) at $82.1 million in Q1 2026, $72.9 million in Q4 2025, and $73.4 million in Q3 2025.